Australia markets closed

Nuvectis Pharma, Inc. (NVCT)

NasdaqCM - NasdaqCM Real-time price. Currency in USD
Add to watchlist
6.73-0.04 (-0.59%)
As of 09:43AM EDT. Market open.
Currency in USD

Valuation measures4

Market cap (intra-day) 124.27M
Enterprise value 104.81M
Trailing P/E N/A
Forward P/E N/A
PEG ratio (5-yr expected) N/A
Price/sales (ttm)N/A
Price/book (mrq)8.86
Enterprise value/revenue N/A
Enterprise value/EBITDA -7.38

Trading information

Stock price history

Beta (5Y monthly) 0.48
52-week change 3-62.39%
S&P500 52-week change 323.76%
52-week high 318.29
52-week low 35.85
50-day moving average 36.72
200-day moving average 38.78

Share statistics

Avg vol (3-month) 385.03k
Avg vol (10-day) 361.78k
Shares outstanding 518.36M
Implied shares outstanding 618.57M
Float 86.35M
% held by insiders 153.64%
% held by institutions 116.70%
Shares short (15 May 2024) 41.02M
Short ratio (15 May 2024) 410.92
Short % of float (15 May 2024) 411.13%
Short % of shares outstanding (15 May 2024) 45.57%
Shares short (prior month 15 Apr 2024) 4822.55k

Dividends & splits

Forward annual dividend rate 4N/A
Forward annual dividend yield 4N/A
Trailing annual dividend rate 30.00
Trailing annual dividend yield 30.00%
5-year average dividend yield 4N/A
Payout ratio 40.00%
Dividend date 3N/A
Ex-dividend date 4N/A
Last split factor 2N/A
Last split date 3N/A

Financial highlights

Fiscal year

Fiscal year ends 31 Dec 2023
Most-recent quarter (mrq)31 Mar 2024

Profitability

Profit margin 0.00%
Operating margin (ttm)0.00%

Management effectiveness

Return on assets (ttm)-77.22%
Return on equity (ttm)-170.23%

Income statement

Revenue (ttm)N/A
Revenue per share (ttm)N/A
Quarterly revenue growth (yoy)N/A
Gross profit (ttm)N/A
EBITDA N/A
Net income avi to common (ttm)-22.38M
Diluted EPS (ttm)-1.41
Quarterly earnings growth (yoy)N/A

Balance sheet

Total cash (mrq)19.46M
Total cash per share (mrq)1.06
Total debt (mrq)N/A
Total debt/equity (mrq)N/A
Current ratio (mrq)3.46
Book value per share (mrq)0.76

Cash flow statement

Operating cash flow (ttm)-15.54M
Levered free cash flow (ttm)-7.02M